MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage many intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal trial objectives have been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, whilst one of several ... https://n-acetylcysteineamide77543.daneblogger.com/30249768/what-does-nemifitide-ditfa-mean